CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption
- 15 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 26 (4), 519-+
- https://doi.org/10.1038/s41591-020-0782-y
Abstract
Immune checkpoint blockade has been proposed as a potentially curative strategy to reduce the HIV reservoir. Studies in monkeys now show that this approach alone is ineffective at enabling viral control after antiretroviral treatment interruption. The primary human immunodeficiency virus (HIV) reservoir is composed of resting memory CD4(+) T cells, which often express the immune checkpoint receptors programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), which limit T cell activation via synergistic mechanisms. Using simian immunodeficiency virus (SIV)-infected, long-term antiretroviral therapy (ART)-treated rhesus macaques, we demonstrate that PD-1, CTLA-4 and dual CTLA-4/PD-1 immune checkpoint blockade using monoclonal antibodies is well tolerated, with evidence of bioactivity in blood and lymph nodes. Dual blockade was remarkably more effective than PD-1 blockade alone in enhancing T cell cycling and differentiation, expanding effector-memory T cells and inducing robust viral reactivation in plasma and peripheral blood mononuclear cells. In lymph nodes, dual CTLA-4/PD-1 blockade, but not PD-1 alone, decreased the total and intact SIV-DNA in CD4(+) T cells, and SIV-DNA and SIV-RNA in B cell follicles, a major site of viral persistence during ART. None of the tested interventions enhanced SIV-specific CD8(+) T cell responses during ART or viral control after ART interruption. Thus, despite CTLA-4/PD-1 blockade inducing robust latency reversal and reducing total levels of integrated virus, the degree of reservoir clearance was still insufficient to achieve viral control. These results suggest that immune checkpoint blockade regimens targeting PD-1 and/or CTLA-4, if performed in people living with HIV with sustained aviremia, are unlikely to induce HIV remission in the absence of additional interventions.This publication has 54 references indexed in Scilit:
- Maintenance of Intestinal Th17 Cells and Reduced Microbial Translocation in SIV-infected Rhesus Macaques Treated with Interleukin (IL)-21PLoS Pathogens, 2013
- PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaquesJCI Insight, 2012
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineNature, 2011
- SPICE: Exploration and analysis of post‐cytometric complex multivariate datasetsCytometry Part A, 2011
- New Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the Performance of PhyML 3.0Systematic Biology, 2010
- Enhancing SIV-specific immunity in vivo by PD-1 blockadeNature, 2008
- Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathwaysImmunological Reviews, 2008
- HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDSBlood, 2006
- CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaquesBlood, 2006
- Control of Effector CD8 + T Cell Function by the Transcription Factor EomesoderminScience, 2003